Serious adverse events with a greater than @ % frequency with tecemotide were pneumonia ( @ -LSB- @ % -RSB- in the tecemotide group vs @ -LSB- @ % -RSB- in the placebo group ) , dyspnoea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and metastases to central nervous system ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .